The US FDA has granted expanded clearance for the DigniCap Cooling System to include use in patients undergoing chemotherapy for solid tumors in other areas of the body besides the breast.
Risk of chemotherapy-induced hair loss common to breast cancer therapy may be reduced with the use of scalp-cooling device.
A patient's self image can reduce his or her coping abilities and can be significantly impacted by this distressing side effect.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|